Anne S. Tsao, MD, and Edward B. Garon, MD, MS, introduce themselves and provide an overview of the incidence, prognosis, and treatment of non–small cell lung cancer.
Videos
Michael Hurwitz, MD, PhD, discusses the advances being made for the treatment of chimeric antigen receptor T-cell therapies and next steps for evaluating the agent across solid tumors.
A glimpse into the ever-changing treatment landscape of DLBCL, exploring frontline therapy options and the potential for tailoring treatments based on novel agents and randomized trials.
Dr. Lunning explores the FDA-approved CD3- and CD20-targeting bispecifics in relapsed/refractory DLBCL, highlighting their potential impact on heavily pretreated patients.
A comprehensive exploration of CAR T-cell therapy and additional agents such as loncastuximab in relapsed/refractory DLBCL, emphasizing clinical findings and treatment considerations.
A deep dive into the use of Polatuzumab Vedotin in DLBCL treatment, including insights from clinical trials and innovative strategies.
Matthew Lunning, DO, FACP, further explores relapsed/refractory DLBCL treatment strategies and clinical trial findings from the L-MIND and RE-MIND2 studies, discussing the impact of tafasitamab + lenalidomide on patient outcomes.
An in-depth examination of relapsed/refractory DLBCL treatment options, including CAR T-cell therapy and tafasitamab, based on clinical trial data and patient eligibility.
Expert insights into a 67-year-old man's journey through relapsed/refractory diffuse large B-cell lymphoma, exploring diagnosis, treatment options, and outcomes.
Bradley J. Monk, MD, FACS, FACOG, discusses the phase 3 KEYNOTE-A18 study of pembrolizumab with chemoradiotherapy for the treatment of patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.
Anthony Hunter, MD, details the primary goals when treating a typical patient with myelofibrosis, such as improving symptoms like weight loss and fatigue, addressing anemia, and, more recently, striving to extend survival, with treatments like JAK inhibitors showing potential for improving overall survival in patients.
Myelofibrosis can be categorized as primary (developing de novo) or secondary (arising in patients with pre-existing MPNs), and it further distinguishes between proliferative and cytopenic types, with each type having its unique diagnostic criteria and implications for treatment.
Rafael Fonseca, MD, envisions a future where bispecific antibodies and CAR T-cell therapy, currently used in advanced stages of multiple myeloma treatment, can offer potential cure for patients, and emphasizes the importance of advocating for their broader application in community settings.
Hussein Tawbi, MD, PhD, presents the case of a 67-year-old woman with stage IV melanoma and shared his initial impressions.
An expert oncologist discusses novel treatments for relapsed/refractory multiple myeloma presented at recent meetings, highlighting a study on elranatamab, a new compound targeting BCMA, and trials including the LINKER-MM1 study on linvoseltamab.
Hussein Tawbi, MD, PhD, emphasizes the importance of patient education in managing adverse events from the treatment of metastatic melanoma with checkpoint inhibition, discussing symptom recognition, potential side effects, and treatment adjustments while ensuring team accessibility and patient communication.
Hatem Soliman, MD, discusses future directions for the HER2-positive breast cancer treatment landscape.
Following their program with expert Alexander Spira, MD, PhD, FACP, Oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, share key takeaways from ESMO 2023 centered on advancements in the management of NSCLC.
Alexander Spira, MD, PhD, FACP, joins the Oncology Brothers in reviewing data from LIBRETTO-431 and frontline selpercatinib in patients with RET fusion–positive advanced non–small cell lung cancer.
Shared insight from key opinion leaders on results from MARIPOSA-2 and the role of amivantamab plus lazertinib and chemotherapy in patients with advanced NSCLC following progression on osimertinib.
Expert insight into results from MARIPOSA, a study of frontline amivantamab plus lazertinib in advanced non–small cell lung cancer, and the potential for this regimen’s use in real-world practice.
Oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Alexander Spira, MD, PhD, FACP, to review data from PAPILLON, which combined amivantamab and chemotherapy as frontline treatment for patients with advanced NSCLC.
Pierre Gholam, MD, discusses the phase 3 RATIONALE-301 study of frontline tislelizumab vs sorafenib for patients with hepatocellular carcinoma.
Viktor Grünwald, MD, PhD, discusses what findings from the post hoc analysis of the CLEAR trial of lenvatinib plus pembrolizumab vs sunitinib for patients with renal cell carcinoma mean for community oncologists.
Arnab Basu, MD, MPH, FACP, discusses molecular residual disease-guided adjuvant therapy in patients with renal cell carcinoma, highlighting the rationale and goals of the MRD gate RCC clinical trial.
Hossein Borghaei, MS, DO, provides an overview on his presentation given at the 18th Annual New York Lung Cancers Symposium.
Alan Tan, MD, discusses areas of interest in the research and development of circulating tumor DNA in renal cell carcinoma.
Paul Lammers, MD, MSc, talks about the future of cell therapies and the applications of TAC-01 in solid tumors.
Treatment goals for patients with myelofibrosis include prolonged survival and improved quality of life, with decision-making incorporating risk level, transplant eligibility, toxicity, and clinical trial data to select among the available JAK inhibitors.
Abdulraheem Yacoub, MD, provides an overview of myelofibrosis, including diagnosis via bone marrow examination, clinical criteria, and risk stratification using prognostic models to determine appropriate therapy.